

Professor Andrew Tutt's publications

Peer-reviewed publications

- Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, BCSC (UK), TNT TMG, Evans DG, Ross G, Eccles D, Tutt A, Rahman N (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years BJC (In press).
- Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Puztai L (2011) Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer Ann Surg Oncol (Epub ahead of print).
- Glendenning J, Irshad S, Tutt A (2011) Treatment of Metastatic Triple-negative Breast Cancer Curr Breast Cancer Rep (In press).
- Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotirou C, Piccart-Gebhar M (2011) Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol (In press).
- Glendenning J, Tutt A (2011) PARP inhibitors - current status and the walk towards early breast cancer Breast Suppl 3:S12-9.
- Julien S, Ivetic A, Grigoriadis A, Qize D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM (2011) Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers Cancer Res 71(24):7683-93.
- Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth G, Kelleher M, Shamil E, Zhang R, Selvin PR, Santis G, Spicer J, Woodman N, Gillett CE, Barber PR, Vojnovic B, Keri G, Schaeffter T, Goh V, O'Doherty MJ, Ellis PA, Ng T *Tutt A acknowledged (2011) The challenges of integrating molecular imaging into the optimization of cancer therapy Integrative Biology (In press).
- Jiao Y, Lawler K, Patel GS, Purushotham A, Jones AF, Grigoriadis A, Tutt A, Ng T, Teschendorff AE (2011) DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference BMC Bioinformatics 12:403.
- Balmana J, Domchek S, Tutt A, Garber J (2011) Landmines on the path to personalized medicine in breast cancer: The case of PARP inhibitors for BRCA1/2 – associated cancers Cancer Discovery 1(1); 29-34.

- Irshad S, Ellis P, Tutt A (2011) Molecular heterogeneity of triple-negative breast cancer and its clinical implications *Curr Opin Oncol* 23(6):566-77.
- Domchek SM, Mitchell G, Lindeman GJ, Tung NM, Balmaña J, Isakoff SJ, Schmutzler R, Audeh MW, Loman N, Scott C, Friedlander M, Kaufman B, Garber JE, Tutt A, Robson ME (2011) Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer *J Clin Oncol* 29(32):4224-6.
- Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC (2011) Biologic markers determine both the risk and the timing of recurrence in breast cancer *Breast Cancer Res Treat* 129(2):607-16.
- Irshad S, Ashworth A, Tutt A (2011) Therapeutic Potential of PARP inhibitors for Metastatic Breast Cancer *Expert Rev Anticancer Ther* 11(8):1243-51.
- Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M (2011) Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses *Breast Cancer Res Treat* 130(2):609-18.
- Vichapat V, Gillett C, Fentiman IS, Tutt A, Holmberg L, Lüchtenborg M (2011) Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways *Eur J Cancer* 13:1919-27.
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, Panel members (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 *Ann Oncol* 8:1736-47.
- Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial *The Lancet* 376(9737):235-44.
- Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A (2010) A multicentre phase II study of the oral PARP inhibitor olaparib (AZD2281; KU-0059436) in BRCA1 or BRCA2 mutation carriers with recurrent ovarian cancer *The Lancet* 376(9737):245-51.
- Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, Tutt A, Tulasne D, Le Bourhis X, Delano P (2010) GD synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation *Mol Cancer Res* 11:1526-35.
- Molyneux G, Geyer FC, Magnay F-A, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ (2010) BRCA1 Basal-like breast cancers originate from luminal epithelial progenitors not from basal stem cells *Cell Stem Cell* 3:403-17.
- Yap TA, de Bono JS, Kaye S, Tutt A, Ashworth A, Schellens JHM (2010) Reply to J. Veeck et al. *JCO* vol. 28 no. 29 e565-e566.

- Uva P, Lahm A, Sbardellati A, Grigoriadis A, Tutt A, de Rinaldis E (2010) Comparative Membranome expression analysis in primary tumors and derived cell lines PLoS One 7:e11742.
- Pichert G, Jacobs C, Jacobs I, Menon U, Manchanda R, Johnson M, Hamed H, Firth C, Evison M, Tutt A, de Silva L, Langman C, Izatt I (2010) Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers Fam Cancer 3:313-9.
- Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer Cancer Res 5:2085-94.
- Stebbing J, Ellis P, Tutt A (2010) PARP inhibitors in BRCA1/ BRCA2 associated and triple negative breast cancers Future Oncology 4:485-6.
- Loi S, Haibe-Kain B, Maijaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt ANJ, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotirou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer PNAS 22:10208-13.
- Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourly C, de Greve J, Lubinski J, Shanley S, Messiou C, A'hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JHM, de Bono JS, Kaye SB, (2009) Poly(ADP)-ribose polymerase (PARP) inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 15:2512-9.
- Yap TA, Kaye SB, Ashworth A, Tutt AN (2009) Tumour-specific synthetic lethality: targeting BRCA dysfunction in Ovarian Cancer Chapter 7 in Emerging Therapeutic Targets in Ovarian Cancer, Springer
- Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers NEJM 2:123-34.
- Natrajan R, Lambros MB, Rodríguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchió C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS (2009) Tiling path genomic profiling of grade 3 invasive ductal breast cancers Clin Cancer Res 15: 2711-2722
- Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK (2009) Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer Clin Oncol (R Coll Radiol) 6: 448-50.
- Iverson AA, Gillett C, Cane P, Santini CD, Vess TM, Kam-Morgan L, Wang A, Eisenberg M, Rowland CM, Hessling JJ, Broder SE, Sninsky JJ, Tutt A,

- Anderson S, Chang SYP (2009) A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. *J Mol Diag* 11: 117-130
- Hiley C, Tutt A, Torres M, Palmieri C (2009) Adjuvant radiotherapy for breast cancer *BMJ* 337:a2843
 - Tutt A, Ashworth A (2008) Can genetic testing guide treatment in breast cancer? *Eur J Cancer* 18: 2774-80
 - Tutt A, Wang A, Lau K, Gillett C, Chew K, Rowland C, Dai H, Kwok S, Ryder K, Shu H, Springall R, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F (2008) Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. *BMC Cancer* 8: 339
 - Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AN, Gillett C, Ellis P, Ryder K, Reid J, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. *BMC Genomics* 9: 239
 - Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A (2008) A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. *EMBO J* 27: 1368-77
 - Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A (2008) Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer. *Cancer Cell* 13: 91-104
 - Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. *Histopathology* 52: 108-18
 - Kilburn, LS, TNT Trial Management Group (2007) 'Triple Negative' Breast Cancer: A New Area for Phase III Breast Cancer Clinical Trials. *Clinical Oncology* 20: 35-39
 - Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS (2007) Are triple negative tumours and basal-like breast cancer synonymous? *Breast Cancer Res.* 9(6): 404
 - Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AN, Gillett C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. *J Clin Oncol.* 25: 1239-46
 - Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN (2007) BRCA1 dysfunction in Sporadic Basal-like Breast Cancer *Oncogene* 26: 2126-32

- Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt AN, Bancroft E, Short S, Smith I, Gui G; Royal Marsden NHS Foundation Trust; Barr L, Baidam A, Howell A, Royle G, Pierce L, Easton D, Eeles R (2006) Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom Clin Cancer Res. 12: 7033-8
- Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt AN, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust; Barr L, Baidam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. (2006) Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 12: 7025-32
- McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor M, Tutt AN, Zdzienicka M, Smith G, Ashworth A (2006) Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to PARP Inhibition. Cancer Res 15;66: 8109-15
- Tutt A, Yarnold J (2006) Radiobiology of breast cancer. Clin Oncol (R Coll Radiol). 18: 166-78
- McCabe N, Lord CJ, Tutt AN, Martin NMB, Smith GCM, Ashworth A (2005) BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency. Cancer Biol Ther. 4: 934-6
- Tutt AN, Lord CJ, McCabe N, Farmer H, Turner NC, Jackson, SP, Smith GCM, Ashworth A (2005) Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer Cold Spring Harb Symp Quant Biol. 70: 139-48
- Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 5: 388-93
- Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 14;434(7035): 917-21
- Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A (2004) DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep. 5: 989-93
- Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-9
- Tutt ANJ, Plunkett TA, Barrington SF, Leslie MD (2004) The role of positron emission tomography in the management of colorectal cancer. Colorectal Disease 6: 2-9
- Tutt A, Ashworth A (2003) Close relatives or distant cousins? Lancet Oncol. 4: 593-4

- Tutt A, Connor F, Bertwistle D, Kerr P, Peacock J, Ross G, Ashworth A (2003) Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity. *Oncogene* 22: 2926-31
- Tutt AN, Ashworth A (2002) The relationship between the Roles of BRCA genes in DNA repair and cancer predisposition. *Trends in Molecular Medicine* 32: 3617-27
- Tutt AN, van Oostrom CT, Ross GM, van Steeg H, Ashworth A (2002) Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation. *EMBO Rep.* 3: 255-60
- Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, Griffin C, Thacker J, Ashworth A (2001) Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. *EMBO J.* 20: 4704-16
- Tutt A, Ross G (2000) Much still to learn about relations between tumour biology, prognosis, and treatment outcome in early breast cancer. *BMJ.* 320(7233): 478-9
- Tutt A, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A (1999) Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. *Curr Biol.*9: 1107-10
- Tutt AN, Lodge N, Blake PR (1999) Palliative chemotherapy in recurrent carcinoma of the cervix: an audit of the use of ifosfamide and review of the literature. *Int J Gynecol Cancer.* 9: 12-17
- Hammick M, Tutt A, Tait DM (1998) Knowledge and perception regarding radiotherapy and radiation in patients receiving radiotherapy: a qualitative study. *Eur J Cancer Care (Engl).* 7: 103-12
- Tutt AN, Brada M, Sampson SA (1997) Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder. *Gut.* 40: 801-3
- Fisher NC, Tutt A, Sim E, Scarpello JH, Green JR (1996) Collagenous colitis responsive to octreotide therapy. *J-Clin-Gastroenterol.* 23: 300-1

Book chapters

- Emanuele de Rinaldis Andrew Tutt Gabriela Dontu. Chapter 28 Breast Cancer: Emerging Methods for the Assessment of Primary Tumors. In *Breast Cancer: Emerging Methods for the Assessment of Primary Tumors* O'Malley & Pinder & Mulligan ISBN: 978-1-4377-1757-0; PII: B978-1-4377-1757-0.00028-7
- Tutt AN, Gregory K (2003) Managing the side effects of therapy. In *Cancer in Primary Care*, Gore M, Russell D (ed) Isis Medical Media

- Ross GM, Landau D, Tutt ANJ (2002) Adjuvant Radiotherapy in the Management of Breast Cancer. In Medical Therapy for Breast Cancer, Rayter Z, Mansi J (ed) pp. 178-208. Cambridge: Cambridge University Press
- Tutt ANJ, Nutting C, Ross GM (1998) Indications for and value of radiotherapy in the treatment of pain in cancer patients. In Interdisciplinary pain management in cancer patients. Strategies in acute and long term therapy, Bartsch HH, Hornstein W Frhr v (ed) In Cancer Therapy and rehabilitation - contributions from Freiburg Bartsch HH (series ed) Karger.